All In Biotech

Drug Trial Radar · NCT04055909

Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock

Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock. A Randomized, Double-blind, Placebo Controlled Dose Selection Study

Last checked: Nov 19, 2026Latest source record: Apr 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 355 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

355

Actual

Start

Nov 13, 2019

Primary completion

May 9, 2022

Study completion May 9, 2023

Sponsor

Lead sponsor
InotremIndustry
Sponsor type
Industry
First posted
Aug 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled dose-selection study in which two doses of nangibotide are tested versus placebo.

Conditions

  • Shock, Septic

Interventions

  • nangibotide low doseDrug

    nangibotide 0.3 mg/kg/h

  • nangibotide high doseDrug

    nangibotide 1.0 mg/kg/h

  • placeboDrug

    matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sequential organ failure assessment (SOFA) scoreTime frame: day 5

Locations

43 sites in 6 countries. Site status is shown where the registry gives one.

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Ziekenhuis Oost-Limburg

    Genk, Belgium

  • UZ Gent

    Ghent, Belgium

  • Centre hospitalier Jolimont-Lobbes

    La Louvière, Belgium

  • CHU Marie Curie

    Lodelinsart, Belgium

  • Clinique Saint-Pierre

    Ottignies, Belgium

  • CHU UCL Namur asbl

    Yvoir, Belgium

  • Nordsjællandshospital Hillerød

    Hillerød, Denmark

  • Helsinki University Hospital Adult ICU PPDS

    Helsinki, Finland

  • Kuopion Yliopistollinen sairaala

    Kuopio, Finland

  • Tampereen yliopistollinen sairaala

    Tampere, Finland

  • CHU Angers

    Angers, France

  • Centre hospitalier Victor Dupouy

    Argenteuil, France

  • Centre hospitalier de Béthune

    Béthune, France

  • Hôpital Fleyriat

    Bourg-en-Bresse, France

  • CHU Dijon - Hôpital François Mitterrand

    Dijon, France

  • CHD les Oudairies

    La Roche-sur-Yon, France

  • Hôpital de Bicêtre

    Le Kremlin-Bicêtre, France

  • CHU LE Mans

    Le Mans, France

  • CHRU Lille - Hôpital Roger Salengro

    Lille, France

  • Hôpital Universitaire Dupuytren

    Limoges, France

  • Centre Hospitalier Lyon Sud

    Lyon, France

  • Hôpital Nord

    Marseille, France

  • Centre hospitalier de Melun

    Melun, France

  • CHRU Nancy - Hôpital Central

    Nancy, France

  • Hôtel Dieu - Nanates

    Nantes, France

  • CHU de Nîmes

    Nîmes, France

  • Hôpital de la source

    Orléans, France

  • Hôpital Lariboisière

    Paris, France

  • Hôpital Saint Louis

    Paris, France

  • Groupe hospitalier Pitié-Salpêtrière

    Paris, France

  • Hôpital Cochin

    Paris, France

  • CHRU Hôpital Bretonneau

    Tours, France

  • Hôpital d'instruction des Armées Robert Picqué

    Villenave-d'Ornon, France

  • St Jame's Hospital

    Dublin, Ireland

  • Galway University Hospital

    Galway, Ireland

  • Hospital del mar

    Barcelona, Spain

  • Hospital Universitario Vall d'Hebrón

    Barcelona, Spain

  • Hospital Clinical San Carlos

    Madrid, Spain

  • Hospital Universitario Dentral de Asturias

    Oviedo, Spain

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.